On the latest episode of NCPA’s official podcast "Independent Rx Forum," we revisit a conversation from our 2025 Annual Convention with Brian Connelly, president and CEO of TheracosBio, about Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with Type 2 diabetes.
Co-hosts John Beckner and Ed Cohen speak with Connelly about how the company’s model bypasses PBMs to offer pharmacists and patients a fair, transparent price. Listen here or wherever you get your podcasts.
NCPA
